Document Detail


Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol.
MedLine Citation:
PMID:  9505927     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure. DESIGN: A double blind placebo controlled randomised trial. SETTING: University teaching Hospital. PATIENTS: 50 patients with stable chronic heart failure (NYHA class II-IV) due to idiopathic dilated, ischaemic, or hypertensive cardiomyopathy, with left ventricular ejection fraction < 0.45. INTERVENTIONS: Celiprolol 200 mg daily (n = 21), metoprolol 50 mg twice daily (n = 19), or placebo (n = 10) for three months with a four week dose titration period. After the double blind period, patients entered an open label study (with placebo group receiving beta blockers) and were assessed after one year. MAIN OUTCOME MEASURES: Clinical response, efficacy, and tolerance were assessed by the Minnesota heart failure symptom questionnaire six minute walk test, Doppler echocardiography (systolic and diastolic function), radionuclide ventriculography, and atrial and brain natriuretic peptides measured at baseline and after three months. RESULTS: In the metoprolol group at 12 weeks v baseline there was a 47% reduction in symptom score (p < 0.001), improvement of NYHA class (mean (SEM), 2.6 (0.12) to 1.9 (0.13), p = 0.001), exercise distance (1246 (54) to 1402 (52) feet, p < 0.001), and left ventricular ejection fraction (26.9(3.1)% to 31(3.0)%, p = 0.016), and a fall in heart rate (resting, 79 (3) to 62 (3) beats/min, p < 0.001). In the celiprolol group there was a 38% reduction in symptom score (p = 0.02), less improvement in exercise distance (1191 (55) to 1256 (61) feet, p = 0.05), and no significant changes in NYHA class, left ventricular ejection fraction, or heart rate. Mortality at one year was 11% in metoprolol and 19% in the celiprolol group, and symptomatic improvement was maintained in the survivors. CONCLUSIONS: Both drugs were well tolerated but the vasodilator properties of celiprolol do not seem to provide any obvious additional benefit in the long term treatment of heart failure.
Authors:
J E Sanderson; S K Chan; C M Yu; L Y Yeung; W M Chan; K Raymond; K W Chan; K S Woo
Related Documents :
8201777 - Importance of total leg muscle mass for exercise intolerance in chronic heart failure.
8522687 - Relation of systemic and local muscle exercise capacity to skeletal muscle characterist...
16382297 - Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.
1777787 - Accuracy of pulse oximeters in estimating heart rate at rest and during exercise.
60567 - Exercise vectorcardiography in diagnosis of ischaemic heart-disease.
15288137 - Apparent diffusion coefficient of intervertebral discs related to matrix composition an...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  79     ISSN:  1355-6037     ISO Abbreviation:  Heart     Publication Date:  1998 Jan 
Date Detail:
Created Date:  1998-03-23     Completed Date:  1998-03-23     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  86-92     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital. jesanderson@cuhk.edu.hk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Aged
Analysis of Variance
Celiprolol / therapeutic use*
Chi-Square Distribution
Double-Blind Method
Electrocardiography, Ambulatory
Exercise Test
Female
Follow-Up Studies
Heart Failure / drug therapy*,  mortality,  physiopathology
Humans
Male
Metoprolol / therapeutic use*
Middle Aged
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 37350-58-6/Metoprolol; 56980-93-9/Celiprolol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphomet...
Next Document:  Granulocyte colony stimulating factor in neutropenic patients with infective endocarditis.